Search

Your search keyword '"Onuoha, Shimobi"' showing total 48 results

Search Constraints

Start Over You searched for: Author "Onuoha, Shimobi" Remove constraint Author: "Onuoha, Shimobi"
48 results on '"Onuoha, Shimobi"'

Search Results

1. Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies

2. Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR

3. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

4. Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR

6. Designer Small-Molecule Control System Based on Minocycline-Induced Disruption of Protein–Protein Interaction

9. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

11. Designer small molecule control system based on Minocycline induced disruption of protein-protein interaction.

13. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

14. AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies

15. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

17. Targeting the T cell receptor [beta]-chain constant region for immunotherapy of T cell malignancies

18. Anti-CD21 Chimeric Antigen Receptor T cells for the Treatment of T Cell Acute Lymphoblastic Leukemia

20. Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies

22. Anti-CD21 Chimeric Antigen Receptor (CAR)-T Cells for T Cell Acute Lymphoblastic Leukaemia (T-ALL)

23. A High Sensitivity aCD22 CAR Combined with aCD19 CAR to Generate Dual Targeting CAR T Cells for the Treatment of r/r B-ALL

24. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants

25. Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variants

26. Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis

27. Optimised Method for the Production and Titration of Lentiviral Vectors Pseudotyped with the SARS-CoV-2 Spike

28. Combining phage display with SMRTbell next-generation sequencing for the rapid discovery of functional scFv fragments

29. Abstract 1070: AUTO7: Anti-PSMA humanized CAR T-cell with improved persistence and resistance to tumor microenvironment for metastatic castration resistant prostate cancer (mCRPC)

30. Abstract 2183: Targeting TRBC1 and 2 for the treatment of T cell lymphomas

31. Generation of a Highly Sensitive CD22 CAR

32. Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

33. Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

35. Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

36. Structure Guided Engineering of Highly Specific Chimeric Antigen Receptors for the Treatment of T Cell Lymphomas

38. Rational design of antirheumatic prodrugs specific for sites of inflammation

39. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies

42. AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies

47. Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis

48. Prediction of protein biophysical traits from limited data: a case study on nanobody thermostability through NanoMelt.

Catalog

Books, media, physical & digital resources